| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C4BPb |
| Uniprot No | P20851 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 18-252aa |
| 氨基酸序列 | SDA EHCPELPPVD NSIFVAKEVE GQILGTYVCI KGYHLVGKKT LFCNASKEWD NTTTECRLGH CPDPVLVNGE FSSSGPVNVS DKITFMCNDH YILKGSNRSQ CLEDHTWAPP FPICKSRDCD PPGNPVHGYF EGNNFTLGST ISYYCEDRYY LVGVQEQQCV DGEWSSALPV CKLIQEAPKP ECEKALLAFQ ESKNLCEAME NFMQQLKESG MTMEELKYSL ELKKAELKAK LL |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于C4BPb(补体成分4结合蛋白β链)重组蛋白的假设性参考文献示例(内容基于领域内常见研究方向虚构，仅供参考)：
1. **文献名称**: "Recombinant expression and functional characterization of human C4BP β-chain in Escherichia coli"
**作者**: Smith A, et al.
**摘要**: 本研究成功在大肠杆菌系统中表达并纯化重组人C4BPb蛋白，验证其与C4b的结合活性，并证明其可抑制补体经典途径的激活，为补体调控机制研究提供工具。
2. **文献名称**: "Structural insights into the C4BPβ-β2GPI complex in antiphospholipid syndrome"
**作者**: Zhang L, et al.
**摘要**: 通过X射线晶体学解析C4BPb与β2糖蛋白I(β2GPI)的复合物结构，揭示二者在抗磷脂综合征中的病理结合机制，为靶向药物设计提供结构基础。
3. **文献名称**: "Site-directed mutagenesis of C4BPβ reveals critical residues for complement regulation"
**作者**: Tanaka K, et al.
**摘要**: 利用定点突变技术筛选C4BPb中影响补体抑制功能的关键氨基酸位点，发现第113-126位残基对C4b结合及调控补体旁路途径至关重要。
4. **文献名称**: "A mammalian cell-derived recombinant C4BPβ exhibits enhanced stability for therapeutic applications"
**作者**: Müller S, et al.
**摘要**: 开发基于HEK293细胞的重组C4BPb生产系统，获得的蛋白具有正确糖基化和长效稳定性，在败血症模型中显示抑制补体过度激活的潜在治疗价值。
(注：以上文献为模拟生成，实际研究中请通过PubMed或学术数据库检索真实文献。)
C4b-binding protein beta chain (C4BPβ) is a key regulatory component of the complement system, a critical part of innate immunity. C4BP is a large plasma glycoprotein composed of seven identical α-chains and a single β-chain (C4BPβ), forming a spider-like structure. The β-chain plays a distinct role in mediating interactions with protein S, a vitamin K-dependent anticoagulant protein, thereby linking the complement and coagulation systems. This interaction helps regulate both inflammatory responses and thrombotic processes, preventing excessive complement activation and maintaining homeostasis.
C4BPβ is essential for the protein's ability to bind and inactivate C4b, a central component of the classical and lectin complement pathways. By accelerating the decay of C3/C5 convertases and acting as a cofactor for factor I-mediated cleavage of C4b, C4BPβ contributes to limiting tissue damage during infections or autoimmune reactions. Dysregulation of C4BP or its interactions is implicated in thrombotic disorders, autoimmune diseases (e.g., systemic lupus erythematosus), and inflammatory conditions.
Recombinant C4BPβ is produced using expression systems like mammalian cells or bacteria (E. coli) to study its structure-function relationships and therapeutic potential. Engineered versions often include tags for purification and detection. Research focuses on developing C4BPβ-based inhibitors to modulate complement activation in diseases like age-related macular degeneration, atypical hemolytic uremic syndrome, or sepsis. Its role in bridging coagulation and immunity also makes it a target for investigating thrombosis-inflammation cross-talk. As a reagent, recombinant C4BPβ aids in dissecting complement regulation mechanisms and screening for novel therapeutics.
×
